Lowest Price Guaranteed From USD 4,799
Published
September 2023
Pages
552
View Count
40114
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
In most of the cases, hit generation constitutes the majority of the R&D expenditure, leading to around 40% - 50% of the total cost, thus it is expected to hold the majority of the share of the antibody discovery services market.
-- President, US-based small sized company
The global antibody discovery services and platforms market size is estimated to be worth over $1.6 billion in 2023 and is expected to grow at a compounded annual growth rate (CAGR) of 12.0% during the forecast period. The usual drug development process, beginning from discovery to commercialization of a clinically validated product spans around 10-15 years and requires investments of over $2 billion. However, despite the extensive efforts and investments, over 90% of the drug candidates fail in clinical trials. In order to streamline the drug development processes, reduce timelines, and mitigate financial risks associated with failed trials, pharmaceutical players are increasingly outsourcing various aspects of their discovery-stage operations to specialized contract research organizations (CROs). By leveraging the capabilities of such antibody CRO, companies engaged in the antibody discovery market can optimize internal resource utilization and cost saving. Such strategic collaborations allow antibody discovery companies to tap into a global network of scientific talent, which leads to the enhancement of the overall efficiency and success rate of bringing novel antibody-based therapeutics to the market.
Since the approval of the first monoclonal antibody-based therapy, Orthoclone OKT3®, in 1986, such antibodies have evolved into a versatile class of biopharmaceuticals, undergoing significant advancements in engineering, diversification of formats, and innovative discovery methods. Currently, more than 160 monoclonal antibodies have been approved by the various regulatory agencies around the world to be used in humans for the treatment of various diseases, including cancer, chronic inflammatory diseases, infectious diseases and cardiovascular diseases. Some of the recently approved monoclonal antibody therapies include (in reverse chronological order of their approval date) ELREXFIO™ (August 2023), TALVEY™ (August 2023), Rystiggo® (June 2023), COLUMVI® (June 2023) and EPKINLY™ (May 2023). Owing to the complexities associated with the discovery of such monoclonal antibodies, many firms are opting to license and utilize specialized antibody discovery platforms and technologies. Further, given the rising demand for antibody based therapeutics and growing preference for outsourcing, we are led to believe that the opportunity for antibody discovery services and platforms is likely to increase at a significant growth rate in the foreseen future.
The Antibody Discovery Services and Platforms Market (5th Edition): Distribution by Type of Service Offered (Antigen Designing, Hit Generation, Lead Selection, Lead Optimization, Lead Characterization), Antibody Discovery Method (Hybridoma based, Library based, Single Cell based, Transgenic Animal based), Type of Antibody Generated (Monoclonal Antibodies, Bispecific Antibodies and Others), Nature of Antibody Generated (Chimeric, Human, Humanized and Murine), Type of Therapeutic Areas (Cardiovascular Disorders, Immunological Disorders, Infectious Disorders, Neurological Disorders, Oncological Disorders and Others) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunities within the antibody drug discovery services and platforms market during the forecast period. The market report highlights the efforts of the various stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the antibody drug discovery services and platforms market are briefly discussed below.
Outsourcing has been a strategic deployment of the pharmaceutical industry, for the past several decades, where companies delegate their various tasks to external vendors, in order to improve innovation and efficiency of their candidates. The contract research and manufacturing organizations accelerate the development timelines and ensure compliance with stringent regulations through their expertise. These organizations offer risk sharing and transfer and enhance adaptability to market growth. The growing interest in outsourcing of biopharmaceutical operations can be attributed to the need for rapid market access and the rising development costs. As pharmaceutical companies continue to embrace this trend, outsourcing is expected to continue to evolve the industry's landscape, optimizing operations and driving progress in therapeutic innovations.
Recent advancements in biotechnology, increasing demand for targeted therapies, ever-increasing prevalence of chronic diseases, increase in R&D expenditure in pharma and growing trend for outsourcing antibody discovery are some of the key drivers of the antibody drug discovery services and antibody discovery platforms market growth. In addition, the increasing number of collaborations between academic institutions and antibody discovery companies engaged in this industry contributes to the market growth. It is interesting to note that recently, in May 2023, Nona Biosciences signed an agreement with ModeX Therapeutics in order to integrate Harbour Mice® technology into the latter’s MSTAR platform for the discovery of improved treatment options.
Owing to the increase in applications of antibody drug discovery services and platforms, the industry has garnered significant interest from investors, which has resulted in a strong spur in investment activity in this market. For instance, in January 2023, IASO Biotherapeutics USD 75 million in a venture series C round. Further, it is worth highlighting that, in the past two years, four antibody discovery companies (Apexigen, Biocytogen, Shandong Boan Biotechnology and Twist Bioscience) have collectively raised over USD 375 million through initial public offerings. The funds raised by the companies operating in antibody discovery market will continue to advance the development of next generation antibody discovery platforms, which will support the development of novel antibody-based therapeutics driving the market growth over the forecast period.
Furthermore, several companies are entering into mergers and acquisitions to expand the service offerings in the antibody discovery market. In March 2023, Twist Bioscience announced the launch of its antibody discovery services under the Twist Biopharma Solutions subsidiary. The company acquired Abveris, an antibody discovery CRO in 2022 to gain hold of its single cell screening and hybridoma approach.
Licensing of antibody discovery platforms enables the companies to access innovative tools and methods for developing therapeutic antibodies, allowing firms to leverage specialized expertise and expand their R&D capabilities by avoiding the spend on the technology. Recent trends highlight a growing emphasis on collaborations and partnerships between academic institutes, biotechnology startups, and established pharmaceutical companies. Various key players engaged in this market have undertaken various initiatives to out-license / in-license several such antibody discovery platforms. For instance, recently, in June 2023, AbTherx entered into an agreement with Gilead Sciences in order to in-license latter’s novel transgenic mouse technology, named Atlas™ Mice. In addition, in January 2023, Hummingbird Bioscience entered into an agreement with Synaffix in order to utilize Synaffix’s proprietary technologies, GlycoConnect™ and HydraSpace™.
Market Size: Key Segments of the Antibody Drug Discovery Services and Platforms Market
The global market size for antibody drug discovery services and platforms is anticipated to grow at an annualized CAGR of 11.0%, during the forecast period, 2023-2035. At present, the hit generation segment captures the largest market share (40%) of the overall antibody discovery services and platforms market. The hit generation step, which usually employs high-throughput screening and computational methods to accelerate drug discovery, generally accounts for the major proportion of the R&D expenditure in the antibody discovery processes. Given its significance in antibody discovery processes, this trend is unlikely to change during the forecast period. Further, in terms of the antibody discovery method, hybridoma method captures the largest market share (over 30%) of the overall antibody discovery services and platforms market. Owing the capability of hybridoma method to lead the fusion of antibody-producing B cells with myeloma cells in order to create immortalized cell lines capable of continuous antibody manufacturing, this method has proven valuable for generating targeted antibodies for various therapeutic and research applications.
Presently, close to 40% of the market is captured by companies based in North America. Driven by the rising interest in advanced antibody discovery platforms and increasing need for outsourcing in the pharmaceutical industry, the market size for antibody drug discovery services and platforms in North America is anticipated to grow at a CAGR of 12%, during the forecast period, 2023-2035. Several factors contribute to the region’s dominance in this domain, which include the presence of big pharma companies with well-established R&D divisions that foster innovation and drive the demand for advanced antibody discovery platforms.
Examples of key players (which have also been profiled in this market report) engaged in antibody discovery market include (in alphabetical order) Ablexis, Antibody Solutions, ChemPartner, Creative Biolabs, GenScript, Genmab, Harbour BioMed, ImmunoPrecise, Mabsilico, Myrio Therapeutics, Nona Biosciences, Rockland Immunochemicals, Synbio technologies and WuXi Biologics. This market report includes an easily searchable excel database of all the antibody discovery service providers and antibody discovery platform providers worldwide.
Several recent developments have taken place in the field of antibody discovery in terms of both services and platforms. We’ve outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we’ve outlined in our analysis.
The market report presents an in-depth analysis of the various firms / organizations that are engaged in antibody discovery services market, across different segments as defined in the below table:
| Key Report Attributes | Details | |
|
Historical Trend |
2017 – 2021 |
|
|
Base Year |
2022 |
|
|
Forecast Period |
2023 – 2035 |
|
|
Market Size 2023 |
$1.6 Billion |
|
|
CAGR |
12.0% |
|
|
Type of Service Offered |
|
|
|
Antibody Discovery Method |
|
|
|
Type of Antibody Generated |
|
|
|
Nature of Antibody Generated |
|
|
|
Type of Therapeutic Area |
|
|
|
Key Geographical Regions |
|
|
|
Key Companies Profiled |
(Full list of over 350 companies captured available in the report) |
|
|
Customization Scope |
15% Free Customization Option |
|
|
PowerPoint Presentation (Complimentary) |
Available |
|
|
Excel Data Packs (Complimentary) |
|
|
The market research report presents an in-depth analysis, highlighting the capabilities of various companies engaged in this industry, across different geographies. Amongst other elements, the market report features:
One of the key objectives of the market report was to estimate the current opportunity and future growth potential for antibody discovery services and platforms market over the forecast period. We have provided informed estimates on the likely evolution of the market for the forecast period, 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as various steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, animal-based and others), type of antibody generated (monoclonal antibodies, bispecific antibodies and others), nature of antibody generated (chimeric, human, humanized and murine), type of therapeutic areas (cardiovascular disorders, immunological disorders, infectious disorders, neurological disorders, oncological disorders and others) and key geographical regions (North America, Europe and Asia, Latin America, Middle East and North Africa, and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market growth.
The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
Contents
1. PREFACE
1.1. Introduction
1.2. Project Objectives
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Trends Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Structure of Antibodies
5.3. History of Antibody Development
5.4. Antibody Isotypes
5.5. Mechanism of Action of Antibodies
5.6. Classification of Antibodies
5.6.1. Monoclonal Antibodies
5.6.2. Polyclonal Antibodies
5.6.3. Bispecific Antibodies
5.7. Applications of Antibodies
5.8. Concluding Remarks
6. ANTIBODY DISCOVERY: PROCESS AND METHODS
6.1. Chapter Overview
6.2. Antibody Discovery Process
6.2.1. Target Selection and Validation
6.2.2. Hit Generation
6.2.3. Lead Selection
6.2.4. Lead Optimization
6.2.4.1. Humanization
6.2.4.2. Affinity Maturation
6.2.4.3. Fc Engineering
6.2.5. Lead Characterization
6.2.6. Candidate Selection
6.3. Antibody Discovery Methods
6.3.1. Hybridoma Technology-based Method
6.3.2. In vitro Display Method
6.3.2.1. Phage Display
6.3.2.2. Yeast Display
6.3.2.3. Ribosomal Display
6.3.3. Transgenic Animal-based Method
6.3.4. Single B Cell-based Method
6.3.5. Advantages and Disadvantages of Existing Antibody Discovery Techniques
6.4. Evolution of Monoclonal Antibodies
6.4.1. Fully Human Monoclonal Antibodies
6.5. Concluding Remarks
7. ANTIBODY DISCOVERY SERVICE PROVIDERS: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Antibody Discovery Service Providers: List of Industry Players
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Type of Service Offered
7.2.5. Analysis by Type of Antibody Discovered
7.2.6. Analysis by Type of Antibody Discovery Method
7.2.7. Analysis by Animal Model Used
7.2.8. Analysis by Type of Antibody Discovered and Type of Antibody Discovery Method
7.2.9. Analysis by Type of Antibody Discovery Services and Location of Headquarters
7.2.10. Analysis by Application Area
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Competitiveness Analysis: Companies Grouped based on Company Size
8.4.1. Very Small Companies Offering Antibody Discovery Services
8.4.2. Small Companies Offering Antibody Discovery Services
8.4.3. Mid-sized Companies Offering Antibody Discovery Services
8.4.4. Large Companies Offering Antibody Discovery Services
8.5. Antibody Discovery Service Providers: Regional Capability
8.5.1. Antibody Discovery Service Providers based in North America
8.5.2. Antibody Discovery Service Providers based in Europe
8.5.3. Antibody Discovery Service Providers based in Asia
9. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS
9.1. Chapter Overview
9.2. Antibody Discovery Service Providers in North America
9.2.1. Abwiz Bio
9.2.1.1. Company Overview
9.2.1.2. Recent Developments and Future Outlook
9.2.2. Aragen Bioscience (Subsidiary of GVK BIO)
9.2.2.1. Company Overview
9.2.2.2. Recent Developments and Future Outlook
9.2.3. Creative Biolabs
9.2.3.1. Company Overview
9.2.3.2. Recent Developments and Future Outlook
9.2.4. Distributed Bio
9.2.4.1. Company Overview
9.2.4.2. Recent Developments and Future Outlook
9.2.5. ImmunoPrecise Antibodies
9.2.5.1. Company Overview
9.2.5.2. Financial Information
9.2.5.3. Recent Developments and Future Outlook
9.2.6. Integral Molecular
9.2.6.1. Company Overview
9.2.6.2. Recent Developments and Future Outlook
9.2.7. LakePharma
9.2.7.1. Company Overview
9.2.7.2. Recent Developments and Future Outlook
9.2.8. Syd Labs
9.2.8.1. Company Overview
9.2.8.2. Recent Developments and Future Outlook
9.3. Antibody Discovery Service Providers in Europe
9.3.1. Abzena
9.3.1.1. Company Overview
9.3.1.2. Financial Information
9.3.1.3. Recent Developments and Future Outlook
9.3.2. BIOTEM
9.3.2.1. Company Overview
9.3.2.2. Recent Developments and Future Outlook
9.3.3. PX'Therapeutics (Subsidiary of Aguettant Pharmaceutical Group)
9.3.3.1. Company Overview
9.3.3.2. Recent Developments and Future Outlook
9.4. Antibody Discovery Service Providers in Asia and Rest of the World
9.4.1. ChemPartner
9.4.1.1. Company Overview
9.4.1.2. Recent Developments and Future Outlook
9.4.2. HD Biosciences
9.4.2.1. Company Overview
9.4.2.2. Recent Developments and Future Outlook
9.4.3. Viva Biotech
9.4.3.1. Company Overview
9.4.3.2. Financial Information
9.4.3.3. Recent Developments and Future Outlook
9.4.4. WuXi Biologics
9.4.4.1. Company Overview
9.4.4.2. Financial Information
9.4.4.3. Recent Developments and Future Outlook
10. ANTIBODY DISCOVERY TECHNOLOGIES: MARKET LANDSCAPE
10.1. Chapter Overview
10.2. Antibody Discovery: List of Technologies and Platforms
10.2.1. Analysis by Type of Antibody Discovery Method
10.2.2. Analysis by Type of Antibody Discovered
10.2.3. Analysis by Animal Model Used
10.2.4. Analysis by Type of Antibody Discovery Method and Location of Headquarters
10.2.5. Analysis by Type of Antibody Discovery Method and Type of Antibody Discovered
10.3. Antibody Discovery Technologies: List of Industry Players
10.3.1. Analysis by Year of Establishment
10.3.2. Analysis by Company Size
10.3.3. Analysis by Location of Headquarters
10.3.4. Most Active Players: Analysis by Number of Platforms
11. TECHNOLOGY COMPETITIVENESS ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.3. Methodology
11.4. Antibody Discovery Technologies: Competitiveness Analysis
11.4.1. Antibody Discovery Technologies Offered by Companies based in North America
11.4.2. Antibody Discovery Technologies Offered by Companies based in Europe
11.4.3. Antibody Discovery Technologies Offered by Companies based in Asia and Rest of the World
12. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS
12.1. Chapter Overview
12.2. Harbour BioMed
12.2.1. Company Overview
12.2.2. Antibody Discovery Platforms Portfolio
12.2.3. Recent Developments and Future Outlook
12.3. ImmunoPrecise Antibodies
12.3.1. Company Overview
12.3.2. Financial Information
12.3.3. Antibody Discovery Platforms Portfolio
12.3.4. Recent Developments and Future Outlook
12.4. Kymab
12.4.1. Company Overview
12.4.2. Antibody Discovery Platforms Portfolio
12.4.3. Recent Developments and Future Outlook
12.5. Ligand Pharmaceuticals
12.5.1. Company Overview
12.5.2. Financial Information
12.5.3. Antibody Discovery Platforms Portfolio
12.5.4. Recent Developments and Future Outlook
12.6. MorphoSys
12.6.1. Company Overview
12.6.2. Financial Information
12.6.3. Antibody Discovery Platforms Portfolio
12.6.4. Recent Developments and Future Outlook
13. PARTNERSHIPS AND COLLABORATIONS
13.1. Chapter Overview
13.2. Partnership Models
13.3. List of Partnerships and Collaborations
13.3.1. Analysis by Year of Partnership
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Year of Partnership and Type of Partner
13.3.4. Analysis by Type of Antibody
13.3.5. Most Active Players: Analysis by Number of Partnerships
13.3.6. Most Popular Technologies: Analysis by Number of Partnerships
13.3.7. Analysis by Geography
13.3.8. Intracontinental and Intercontinental Agreements
14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. Antibody Discovery Service and Platform Providers: Funding and Investment
14.3.1. Analysis by Year of Funding
14.3.2. Analysis by Type of Funding
14.3.3. Analysis of Amount Invested by Year of Funding
14.3.4. Analysis by Year-wise Number of Funding Instances and Funding Amount
14.3.5. Most Active Players: Analysis by Number of Funding Instances
14.3.6. Most Active Players: Analysis by Amount Invested
14.3.7. Leading Investors: Analysis by Number of Funding Instances
14.3.8. Analysis by Year-wise Number of Funding Instances and Type of Player
14.3.9. Analysis by Year-wise Amount Invested and Type of Player
14.3.10. Analysis of Number of Funding Instances by Year of Establishment and Type of Player
14.3.11. Analysis by Geography
14.4. Concluding Remarks
15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
15.1. Chapter Overview
15.2. Market Drivers
15.3. Market Restraints
15.4. Market Opportunities
15.5. Market Challenges
15.6. Conclusion
16. GLOBAL ANTIBODY DISCOVERY SERVICES MARKET
16.1. Chapter Overview
16.2. Assumptions and Methodology
16.3. Global Antibody Discovery Services Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
16.3.1. Scenario Analysis
16.4. Key Market Segmentations
16..5. Dynamic Dashboard
17. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF SERVICE OFFERED
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Antigen Designing: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.4. Hit Generation: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.5. Lead Selection: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.6. Lead Optimization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.7. Lead Characterization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.8. Data Triangulation and Validation
18. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF ANTIBODY DISCOVERY METHOD
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Phage Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.4. Yeast Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.5. Hybridoma Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.6. Transgenic Animal based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.7. Single Cell based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.8. Other Antibody Discovery Methods: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.9. Data Triangulation and Validation
19. ANTIBODY DISCOVERY SERVICES MARKET, BY NATURE OF ANTIBODY DISCOVERED
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Humanized: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.4. Human: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.5. Chimeric: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.6. Murine: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.7. Data Triangulation and Validation
20. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF THERAPEUTIC AREAS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Oncological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.4. Immunological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.5. Infectious Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.6. Neurological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.7. Cardiovascular Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.8. Other Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.9. Data Triangulation and Validation
21. ANTIBODY DISCOVERY SERVICES MARKET, BY KEY GEOGRAPHIES
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.4. Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.5. Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.6. Latin America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.7. Middle East and North Africa: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.8. Rest of the World: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.9. Data Triangulation and Validation
22. GLOBAL ANTIBODY DISCOVERY TECHNOLOGIES MARKET
22.1. Chapter Overview
22.2. Assumptions and Methodology
22.3. Global Antibody Discovery Technologies Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
22.3.1. Scenario Analysis
22.4. Key Market Segmentations
22.5. Dynamic Dashboard
23. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY TYPE OF ANTIBODY DISCOVERED
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Monoclonal Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.4. Bispecific Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.5. Other Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.6. Data Triangulation and Validation
24. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY KEY GEOGRAPHIES
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.4. Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.5. Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.6. Data Triangulation and Validation
25. LICENSING DEAL STRUCTURE
25.1. Chapter Overview
25.2. Key Parameters
25.3. Assumptions and Methodology
25.3.1. Overall Cash Flow for Licensee Companies
25.3.1.1. Investments Made by a Licensee
25.3.1.2. Revenues Earned by a Licensee
25.3.2. Overall Cash Flow for Licensor Companies
25.3.2.1. Investments Made by a Licensor
25.3.2.2. Revenues Earned by a Licensor
25.4. Key Analytical Outputs
25.4.1. Scenario 1: Variation of Upfront and Milestone Payments
25.4.2. Scenario 2: Variation of Upfront Payments and Sales-based Royalties
25.4.3. Scenario 3: Variation of Milestone Payments and Sales-based Royalties
26. SWOT ANALYSIS: ANTIBODY HUMANIZATION SERVICE PROVIDERS
26.1. Chapter Overview
26.2. Antibody Humanization and Affinity Maturation Service and Platform Providers: List of Players
26.3. Antibody Humanization Service Providers: SWOT Analysis
26.3.1. Strengths
26.3.2. Weaknesses
26.3.3. Opportunities
26.3.4. Threats
27. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES
27.1. Chapter Overview
27.2. Humira® (Adalimumab)
27.2.1. Drug Overview
27.2.2. Discovery Process and Method
27.2.3. Historical Sales
27.3. Keytruda® (Pembrolizumab)
27.3.1. Drug Overview
27.3.2. Discovery Process and Method
27.3.3. Historical Sales
27.4. Stelara® (Ustekinumab)
27.4.1. Drug Overview
27.4.2. Discovery Process and Method
27.4.3. Historical Sales
27.5. Opdivo® (Nivolumab)
27.5.1. Drug Overview
27.5.2. Discovery Process and Method
27.5.3. Historical Sales
27.6. Darzalex® (Daratumumab)
27.6.1. Drug Overview
27.6.2. Discovery Process and Method
27.6.3. Historical Sales
28. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY28.1. Chapter Overview
28.2. Anticipated Shift from Monoclonal Antibodies to Other Novel Antibody Formats
28.3. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
28.4. Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies
28.5. Rising Demand for Antibody-based Treatment Options for Non-Oncological Indications
28.6. Future Growth Opportunities in the Asia and Rest of the World
28.7. Expected Increase in Number of Collaborations and Licensing Activity
28.8 Concluding Remarks
29. CONCLUSION
30. EXECUTIVE INSIGHTS
30.1. Chapter Overview
30.2. Antibody Solutions
30.2.1. Company Snapshot
30.2.2. John S Kenney, Founder and President (Q3 2023)
30.3. Adimab
30.3.1. Company Snapshot
30.3.3. Guy Van Meter, Chief Business Officer (Q3 2023)
30.4. ImmunoPrecise Antibodies
30.4.1. Company Snapshot
30.4.3. Kari Graber, Vice President of Commercial Services (Q3 2023)
30.5. Anonymous
30.5.1. Anonymous, Chief Business Officer (Q3 2023)
30.6. Abveris, Acquired by Twist Biosciences
30.6.1. Company Snapshot
30.6.2. Tracey Mullen, Former Chief Executive Officer (Q2 2020)
30.7. Nidus BioSciences
30.7.1. Company Snapshot
30.7.2. Lisa Delouise, Founder and Chief Technology Officer (Q1 2020)
30.8. AvantGen
30.8.1. Company Snapshot
30.8.2. Mark Kubik, Former Chief Business Officer (Q1 2020)
30.9. Single Cell Technology
30.9.1. Company Snapshot
30.9.2. Chun-Nan Chen, Chief Executive Officer and Chief Scientific Officer (Q2 2018)
30.10. Distributed Bio
30.10.1. Company Snapshot
30.10.2. Giles Day, Co-Founder and Former Chief Executive Officer (Q2 2018)
30.11. AbCellera
30.11.1. Company Snapshot
30.11.2. Kevin Heyries, Co-Founder and Former Lead of Business Development Strategy (Q2 2018)
30.12. AbGenics Life Sciences
30.12.1. Company Snapshot
30.12.2. Sanjiban K Banerjee, Co-founder and Director (Q2 2018)
30.13. CDI Laboratories
30.13.1. Company Snapshot
30.13.2. Ignacio Pino, Co-founder and Chief Executive Officer (Q2 2017)
30.14. AP Biosciences
30.14.1. Company Snapshot
30.14.2. Jeng Her, Chief Executive Officer (Q2 2017)
30.15. YUMAB
30.15.1. Company Snapshot
30.15.2. Thomas Schirrmann, Chief Executive Officer and General Manager (Q2 2017)
30.16. Antibody Solutions
30.16.1. Company Snapshot
30.16.2. Debra Valsamis, Business Development Associate (Q2 2017)
30.17. Ligand Pharmaceuticals
30.17.1. Company Snapshot
30.17.2. Christel Iffland, Senior Vice President (Q2 2017)
30.18. LakePharma
30.18.1. Company Snapshot
30.18.2. Aaron Sato, Former Chief Scientific Officer (Q2 2017)
31. APPENDIX 1: TABULATED DATA
32. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION
Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 4.1 Executive Summary: Market Landscape of Antibody Discovery Service Providers
Figure 4.2 Executive Summary: Market Landscape of Antibody Discovery Platform Providers
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Funding and Investment Analysis
Figure 4.5 Executive Summary: Market Sizing and Opportunity Analysis for Antibody Discovery Services
Figure 4.6 Executive Summary: Market Sizing and Opportunity Analysis for Antibody Discovery Platforms
Figure 5.1 Basic Structure of an Antibody
Figure 5.2 Historical Timeline of Antibody Development
Figure 5.3 Mechanism of Action of Antibodies
Figure 5.4 Applications of Antibodies
Figure 6.1 Overview of the Antibody Discovery Process
Figure 6.2 Antibody Discovery Process: Hybridoma Method
Figure 6.3 Antibody Discovery Process: Phage Display Method
Figure 6.4 Antibody Generation Using Transgenic Animals
Figure 6.5 Approved Monoclonal Antibodies: Development Trend Analysis
Figure 6.6 Approval Timeline of Fully Human Monoclonal Antibodies
Figure 6.7 Discovery Methods of Fully Human Monoclonal Antibodies
Figure 7.1 Antibody Discovery Service Providers: Distribution by Year of Establishment
Figure 7.2 Antibody Discovery Service Providers: Distribution by Company Size
Figure 7.3 Antibody Discovery Service Providers: Distribution by Location of Headquarters
Figure 7.4 Antibody Discovery Service Providers: Distribution by Type of Service Offered
Figure 7.5 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered
Figure 7.6 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
Figure 7.7 Antibody Discovery Service Providers: Distribution by Animal Model Used
Figure 7.8 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered and Type of Antibody Discovery Method
Figure 7.9 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Services and Location of Headquarters
Figure 7.10 Antibody Discovery Service Providers: Analysis by Application Area
Figure 8.1 Competitiveness Analysis: Very Small Companies Offering Antibody Discovery Services
Figure 8.2 Competitiveness Analysis: Small Companies Offering Antibody Discovery Services
Figure 8.3 Competitiveness Analysis: Mid-sized Companies Offering Antibody Discovery Services
Figure 8.4 Competitiveness Analysis: Large Companies Offering Antibody Discovery Services
Figure 8.5 Regional Capability: Benchmarking of Players based in North America
Figure 8.6 Regional Capability: Benchmarking of Players based in Europe
Figure 8.7 Regional Capability: Benchmarking of Players based in Asia
Figure 9.1 ImmunoPrecise Antibodies: Annual Revenues, 2016-2022 (USD Million)
Figure 9.2 Abzena: Annual Revenues, 2016-2022 (GBP Million)
Figure 9.3 Fusion Antibodies: Annual Revenues, 2017-2022 (EUR Million)
Figure 9.4 Viva Biotech: Annual Revenues, 2016-2022 (RMB Million)
Figure 9.5 WuXi Biologics: Annual Revenues, 2016-2022 (RMB Billion)
Figure 10.1 Antibody Discovery Technologies: Distribution by Type of Antibody Discovered
Figure 10.2 Antibody Discovery Technologies: Distribution by Type of Antibody Discovery Method
Figure 10.3 Antibody Discovery Technologies: Distribution by Animal Model Used
Figure 10.4 Antibody Discovery Technologies: Distribution by Type of Antibody Discovery Method and Location of Headquarters
Figure 10.5 Antibody Discovery Technologies: Distribution by Discovery Method and Type of Antibody Discovered
Figure 10.6 Antibody Discovery Technology Providers: Distribution by Year of Establishment
Figure 10.7 Antibody Discovery Technology Providers: Distribution by Company Size
Figure 10.8 Antibody Discovery Technology Providers: Distribution by Location of Headquarters
Figure 10.9 Most Active Players: Distribution by Number of Technologies
Figure 11.1 Competitiveness Analysis: Technologies Offered by Companies based in North America
Figure 11.2 Competitiveness Analysis: Technologies Offered by Companies based in Europe
Figure 11.3 Competitiveness Analysis: Technologies Offered by Companies based in Asia and Rest of the World
Figure 13.1 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2023
Figure 13.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 13.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2021-2023
Figure 13.4 Partnerships and Collaborations: Distribution by Type of Antibody
Figure 13.5 Most Active Players: Distribution by Number of Partnerships
Figure 13.6 Most Popular Technologies: Distribution by Number of Partnerships
Figure 13.7 Partnerships and Collaborations: Distribution by Geography
Figure 13.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 14.1 Funding and Investment Analysis: Cumulative Year-wise Trend, 2016-2023
Figure 14.2 Funding and Investment Analysis: Distribution by Type of Funding
Figure 14.3 Funding and Investment Analysis: Distribution of Amount Invested by Year of Funding, 2016-2023 (USD Million)
Figure 14.4 Funding and Investment Analysis: Distribution by Year-wise Number of Funding Instances and Funding Amount, 2016-2023 (USD Million)
Figure 14.5 Most Active Players: Distribution by Number of Funding Instances
Figure 14.6 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 14.7 Leading Investors: Distribution by Number of Funding Instances
Figure 14.8 Funding and Investment Analysis: Distribution by Year-wise Number of Funding Instances and Type of Player
Figure 14.9 Funding and Investment Analysis: Distribution by Year-wise Amount Invested and Type of Player
Figure 14.1 0 Funding and Investment Analysis: Distribution of Number of Funding Instances by Year of Establishment and Type of Player
Figure 14.1 1 Funding and Investment Analysis: Distribution by Geography
Figure 14.1 2 Funding and Investment Analysis: Concluding Remarks
Figure 15.1 Market Drivers
Figure 15.2 Market Restrainers
Figure 15.3 Market Opportunities
Figure 15.4 Market Challenges
Figure 16.1 Global Antibody Discovery Services Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 16.2 Global Antibody Discovery Services Market, 2023-2035, Optimistic Scenario (USD Million)
Figure 16.3 Global Antibody Discovery Services Market, 2023-2035, Conservative Scenario (USD Million)
Figure 17.1 Antibody Discovery Services Market for Antigen Designing: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 17.2 Antibody Discovery Services Market for Hit Generation: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 17.3 Antibody Discovery Services Market for Lead Selection: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 17.4 Antibody Discovery Services Market for Lead Optimization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 17.5 Antibody Discovery Services Market for Lead Characterization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.1 Antibody Discovery Services Market for Phage Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.2 Antibody Discovery Services Market for Yeast Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.3 Antibody Discovery Services Market for Hybridoma Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.4 Antibody Discovery Services Market for Transgenic Animal based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.5 Antibody Discovery Services Market for Single Cell based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.6 Antibody Discovery Services Market for Other Antibody Discovery Methods: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 19.1 Antibody Discovery Services Market for Humanized Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 19.2 Antibody Discovery Services Market for Human Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 19.3 Antibody Discovery Services Market for Chimeric Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 19.4 Antibody Discovery Services Market for Murine Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.1 Antibody Discovery Services Market for Oncological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.2 Antibody Discovery Services Market for Immunological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.3 Antibody Discovery Services Market for Infectious Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.4 Antibody Discovery Services Market for Neurological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.5 Antibody Discovery Services Market for Cardiovascular Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.6 Antibody Discovery Services Market for Other Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.1 Antibody Discovery Services Market in North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.2 Antibody Discovery Services Market in Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.3 Antibody Discovery Services Market in Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.4 Antibody Discovery Services Market in Latin America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.5 Antibody Discovery Services Market in Middle East and North Africa: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.6 Antibody Discovery Services Market in Rest of the World: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 22.1 Global Antibody Discovery Technologies Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.2 Global Antibody Discovery Technologies Market, 2023-2035, Optimistic Scenario (USD Million)
Figure 22.3 Global Antibody Discovery Technologies Market, 2023-2035, Conservative Scenario (USD Million)
Figure 23.1 Antibody Discovery Technologies Market for Monoclonal Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 23.2 Antibody Discovery Technologies Market for Bispecific Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 23.3 Antibody Discovery Technologies Market for Other Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 24.1 Antibody Discovery Technologies Market in North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 24.2 Antibody Discovery Technologies Market in Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 24.3 Antibody Discovery Technologies Market in Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 25.1 Licensing Agreements: Distribution of Financial Components
Figure 25.2 Technology Licensing Deal: Payment Structure
Figure 26.1 Antibody Humanization Services and Platforms: SWOT Analysis
Figure 26.2 Antibody Humanization Services and Platforms: Strengths
Figure 26.3 Antibody Humanization Services and Platforms: Weaknesses
Figure 26.4 Antibody Humanization Services and Platforms: Opportunities
Figure 26.5 Antibody Humanization Services and Platforms: Threats
Figure 27.1 Humira®: Annual Sales, 2016-2022 (USD Billion)
Figure 27.2 Keytruda®: Annual Sales, 2016-2022 (USD Billion)
Figure 27.3 Stelara®: Annual Sales, 2016-2022 (USD Billion)
Figure 27.4 Opdivo®: Annual Sales, 2016-2022 (USD Billion)
Figure 27.5 Darzalex®: Annual Sales, 2016-2022 (CHF Million)
Figure 28.1 Future Opportunities Related to Upcoming Trends in Drug Discover
Table 5.1 Antibody Isotypes: Key Features
Table 5.2 Mechanism of Action of Therapeutic Antibodies Against Different Target Classes
Table 5.3 Differences Between Polyclonal and Monoclonal Antibodies
Table 7.1 Antibody Discovery Service Providers: Information on Year of Establishment, Company Size, Location of Headquarters
Table 7.2 Antibody Discovery Service Providers: Information on Type of Services Offered
Table 7.3 Antibody Discovery Service Providers: Information on Type of Antibody Discovered
Table 7.4 Antibody Discovery Service Providers: Information on Type of Antibody Discovery Method
Table 7.5 Antibody Discovery Service Providers: Information on Animal Model Used
Table 7.6 Antibody Discovery Service Providers: Information on Application Area
Table 8.1 Regional Capability Analysis: Antibody Discovery Service Providers Based in North America
Table 8.2 Regional Capability Analysis: Antibody Discovery Service Providers Based in Europe
Table 8.3 Regional Capability Analysis: Antibody Discovery Service Providers Based in Asia
Table 9.1 List of Companies Profiled
Table 9.2 Abwiz Bio: Company Snapshot
Table 9.3 Abwiz Bio: Recent Developments and Future Outlook
Table 9.4 Aragen Bioscience: Company Snapshot
Table 9.5 Aragen Bioscience: Recent Developments and Future Outlook
Table 9.6 Creative Biolabs: Company Snapshot
Table 9.7 Creative Biolabs: Recent Developments and Future Outlook
Table 9.8 Distributed Bio: Company Snapshot
Table 9.9 Distributed Bio: Recent Developments and Future Outlook
Table 9.10 ImmunoPrecise Antibodies: Company Snapshot
Table 9.11 ImmunoPrecise Antibodies: Recent Developments and Future Outlook
Table 9.12 Integral Molecular: Company Snapshot
Table 9.13 Integral Molecular: Recent Developments and Future Outlook
Table 9.14 LakePharma: Company Snapshot
Table 9.15 LakePharma: Recent Developments and Future Outlook
Table 9.16 Abzena: Company Snapshot
Table 9.17 Abzena: Recent Developments and Future Outlook
Table 9.18 BIOTEM: Company Snapshot
Table 9.19 BIOTEM: Recent Developments and Future Outlook
Table 9.20 PX'Therapeutics: Company Snapshot
Table 9.21 PX'Therapeutics: Recent Developments and Future Outlook
Table 9.22 ChemPartner: Company Snapshot
Table 9.23 ChemPartner: Recent Developments and Future Outlook
Table 9.24 Viva Biotech: Company Snapshot
Table 9.25 Viva Biotech: Recent Developments and Future Outlook
Table 9.26 WuXi Biologics: Company Snapshot
Table 9.27 WuXi Biologics: Recent Developments and Future Outlook
Table 10.1 Antibody Discovery Technologies: Information on Type of Antibody Discovered
Table 10.2 Antibody Discovery Service Technologies: Information on Type of Antibody Discovery Method
Table 10.3 Antibody Discovery Service Technologies: Information on Animal Model Used
Table 10.4 Antibody Discovery Service Technologies: Information on Location of Headquarters of Developer
Table 10.5 Antibody Discovery Platform Providers: Information on Year of Establishment, Company Size, Location of Headquarters
Table 12.1 List of Companies Profiled
Table 12.2 Ablexis: Company Snapshot
Table 12.3 Ablexis: Antibody Discovery Platform Portfolio
Table 12.4 Ablexis: Recent Developments and Future Outlook
Table 12.5 Creative Biolabs: Company Snapshot
Table 12.6 Creative Biolabs: Antibody Discovery Platform Portfolio
Table 12.7 Creative Biolabs: Recent Developments and Future Outlook
Table 12.8 Genmab: Company Snapshot
Table 12.9 Genmab: Antibody Discovery Platform Portfolio
Table 12.10 Genmab: Recent Developments and Future Outlook
Table 12.11 Harbour BioMed: Company Snapshot
Table 12.12 Harbour BioMed: Antibody Discovery Platform Portfolio
Table 12.13 Harbour BioMed: Recent Developments and Future Outlook
Table 12.14 Immunome: Company Snapshot
Table 12.15 Immunome: Antibody Discovery Platform Portfolio
Table 12.16 Immunome: Recent Developments and Future Outlook
Table 12.17 Isogenica: Company Snapshot
Table 12.18 Isogenica: Antibody Discovery Platform Portfolio
Table 12.19 Isogenica: Recent Developments and Future Outlook
Table 12.20 Kymab: Company Snapshot
Table 12.21 Kymab: Antibody Discovery Platform Portfolio
Table 12.22 Kymab: Recent Developments and Future Outlook
Table 12.23 Ligand Pharmaceuticals: Company Snapshot
Table 12.24 Ligand Pharmaceuticals: Antibody Discovery Platform Portfolio
Table 12.25 Ligand Pharmaceuticals: Recent Developments and Future Outlook
Table 12.26 MorphoSys: Company Snapshot
Table 12.27 MorphoSys: Antibody Discovery Platform Portfolio
Table 12.28 MorphoSys: Recent Developments and Future Outlook
Table 13.1 Antibody Discovery Service and Platform Providers: List of Partnerships and Collaboration, 2015-2023
Table 14.1 Antibody Discovery Service and Platform Providers: List of Funding Instances, 2016-2023
Table 24.1 Developmental / Regulatory Milestones
Table 24.2 Antibody Discovery Platforms: Average Upfront and Average Milestone Payments (USD Million)
Table 25.1 Approved Monoclonal Antibodies: Information on Affinity
Table 25.2 Antibody Humanization: List of Service Providers
Table 26.1 List of Top Ten Selling Therapeutic Antibodies, 2022
Table 29.1 Antibody Solutions: Company Snapshot
Table 29.2 A dimab: Company Snapshot
Table 29.3 I mmunoPrecise Antibodies: Company Snapshot
Table 29.4 A bveris Antibody: Company Snapshot
Table 29.5 N idus BioSciences: Company Snapshot
Table 29.6 A vantGen: Company Snapshot
Table 29.7 S ingle Cell Technology: Company Snapshot
Table 29.8 D istributed Bio: Company Snapshot
Table 29.9 AbCellera: Company Snapshot
Table 29.10 AbGenics Life Sciences: Company Snapshot
Table 29.11 CDI Laboratories: Company Snapshot
Table 29.12 AP Biosciences: Company Snapshot
Table 29.13 YUMAB: Company Snapshot
Table 29.14 Antibody Solutions: Company Snapshot
Table 29.15 Ligand Pharmaceuticals: Company Snapshot
Table 29.16. LakePharma: Company Snapshot
Table 30.1 Antibody Discovery Service Providers: Distribution by Year of Establishment
Table 30.2 Antibody Discovery Service Providers: Distribution by Company Size
Table 30.3 Antibody Discovery Service Providers: Distribution by Location of Headquarters
Table 30.4 Antibody Discovery Service Providers: Distribution by Type of Service Offered
Table 30.5 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered
Table 30.6 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
Table 30.7 Antibody Discovery Service Providers: Distribution by Animal Model Used
Table 30.8 A ntibody Discovery Service Providers: Distribution by Type of Antibody Discovered and Type of Antibody Discovery Method
Table 30.9 A ntibody Discovery Service Providers: Distribution by Type of Antibody Discovery Services and Location of Headquarters
Table 30.10 Antibody Discovery Service Providers: Analysis by Application Area
Table 30.11 ImmunoPrecise Antibodies: Annual Revenues, 2016-2022 (USD Million)
Table 30.12 Abzena: Annual Revenues, 2016-2022 (GBP Million)
Table 30.13 Fusion Antibodies: Annual Revenues, 2017-2022 (EUR Million)
Table 30.14 Viva Biotech: Annual Revenues, 2016-2022 (RMB Million)
Table 30.15 WuXi Biologics: Annual Revenues, 2016-2022 (RMB Billion)
Table 30.16 Antibody Discovery Technologies: Distribution by Type of Antibody Discovered
Table 30.17 Antibody Discovery Technologies: Distribution by Type of Antibody Discovery Method
Table 30.18 Antibody Discovery Technologies: Distribution by Animal Model Used
Table 30.19 Antibody Discovery Technologies: Distribution by Type of Antibody Discovery Method and Location of Headquarters
Table 30.20 Antibody Discovery Technologies: Distribution by Discovery Method and Type of Antibody Discovered
Table 30.21 Antibody Discovery Technology Providers: Distribution by Year of Establishment
Table 30.22 Antibody Discovery Technology Providers: Distribution by Company Size
Table 30.23 Antibody Discovery Technology Providers: Distribution by Location of Headquarters
Table 30.24 Most Active Players: Distribution by Number of Technologies
Table 30.25 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2023
Table 30.26 Partnerships and Collaborations: Distribution by Type of Partnership
Table 30.27 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2021-2023
Table 30.28 Partnerships and Collaborations: Distribution by Type of Antibody
Table 30.29 Most Active Players: Distribution by Number of Partnerships
Table 30.30 Most Popular Technologies: Distribution by Number of Partnerships
Table 30.31 Partnerships and Collaborations: Distribution by Geography
Table 30.32 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 30.33 Funding and Investment Analysis: Cumulative Year-wise Trend, 2016-2023
Table 30.34 Funding and Investment Analysis: Distribution by Type of Funding
Table 30.35 Funding and Investment Analysis: Distribution of Amount Invested by Year of Funding, 2016-2023 (USD Million)
Table 30.36 Funding and Investment Analysis: Distribution by Year-wise Number of Funding Instances and Funding Amount, 2016-2023 (USD Million)
Table 30.37 Most Active Players: Distribution by Number of Funding Instances
Table 30.38 Most Active Players: Distribution by Amount Invested (USD Million)
Table 30.39 Leading Investors: Distribution by Number of Funding Instances
Table 30.40 Funding and Investment Analysis: Distribution by Year-wise Number of Funding Instances and Type of Player
Table 30.41 Funding and Investment Analysis: Distribution by Year-wise Amount Invested and Type of Player
Table 30.42 Funding and Investment Analysis: Distribution of Number of Funding Instances by Year of Establishment and Type of Player
Table 30.43 Funding and Investment Analysis: Distribution by Geography
Table 30.44 Global Antibody Discovery Services Market, Historical Trends, 2017-2022 (USD Million)
Table 30.45 Global Antibody Discovery Services Market, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 30.46 Antibody Discovery Services Market for Antigen Designing, Historical Trends 2017-2022 (USD Million)
Table 30.47 Antibody Discovery Services Market for Antigen Designing, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.48 Antibody Discovery Services Market for Hit Generation, Historical Trends, 2017-2022 (USD Million)
Table 30.49 Antibody Discovery Services Market for Hit Generation, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.50 Antibody Discovery Services Market for Lead Selection, Historical Trends, 2017-2022 (USD Million)
Table 30.51 Antibody Discovery Services Market for Lead Selection, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.52 Antibody Discovery Services Market for Lead Optimization, Historical Trends, 2017-2022 (USD Million)
Table 30.53 Antibody Discovery Services Market for Lead Optimization, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.54 Antibody Discovery Services Market for Lead Characterization, Historical Trends, 2017-2022 (USD Million)
Table 30.55 Antibody Discovery Services Market for Lead Characterization, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.56 Antibody Discovery Services Market for Phage Display, Historical Trends, 2017-2022 (USD Million)
Table 30.57 Antibody Discovery Services Market for Phage Display, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.58 Antibody Discovery Services Market for Yeast Display, Historical Trends, 2017-2022 (USD Million)
Table 30.59 Antibody Discovery Services Market for Yeast Display, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.60 Antibody Discovery Services Market for Hybridoma Method, Historical Trends, 2017-2022 (USD Million)
Table 30.61 Antibody Discovery Services Market for Hybridoma Method, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USDMillion)
Table 30.62 Antibody Discovery Services Market for Transgenic Animal based Method, Historical Trends, 2017-2022 (USD Million)
Table 30.63 Antibody Discovery Services Market for Transgenic Animal based Method, Forecasted Estimates, 2023-2035, Conservative, Base and OptimisticScenarios (USD Million)
Table 30.64 Antibody Discovery Services Market for Single Cell based Method, Historical Trends, 2017-2022 (USD Million)
Table 30.65 Antibody Discovery Services Market for Single Cell based Method, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.66 Antibody Discovery Services Market for Other Antibody Discovery Method, Historical Trends, 2017-2022 (USD Million)
Table 30.67 Antibody Discovery Services Market for Other Antibody Discovery Method, Forecasted Estimates, 2023-2035, Conservative, Base and OptimisticScenarios (USD Million)
Table 30.68 Antibody Discovery Services Market for Humanized Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.69 Antibody Discovery Services Market for Humanized Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.70 Antibody Discovery Services Market for Human Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.71 Antibody Discovery Services Market for Human Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USDMillion)
Table 30.72 Antibody Discovery Services Market for Chimeric Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.73 Antibody Discovery Services Market for Chimeric Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USDMillion)
Table 30.74 Antibody Discovery Services Market for Murine Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.75 Antibody Discovery Services Market for Murine Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.76 Antibody Discovery Services Market for Oncological Disorders, Historical Trends, 2017-2022 (USD Million)
Table 30.77 Antibody Discovery Services Market for Oncological Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.78 Antibody Discovery Services Market for Immunological Disorders, Historical Trends, 2017-2022 (USD Million)
Table 30.79 Antibody Discovery Services Market for Immunological Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.80 Antibody Discovery Services Market for Infectious Disorders, Historical Trends, 2017-2022 (USD Million)
Table 30.81 Antibody Discovery Services Market for Infectious Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.82 Antibody Discovery Services Market for Neurological Disorders, Historical Trends, 2017-2022 (USD Million)
Table 30.83 Antibody Discovery Services Market for Neurological Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.84 Antibody Discovery Services Market for Cardiovascular Disorders, Historical Trends, 2017-2022 (USD Million)
Table 30.85 Antibody Discovery Services Market for Cardiovascular Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.86 Antibody Discovery Services Market for Other Disorders, Historical Trends, 2017-2022 (USD Million)
Table 30.87 Antibody Discovery Services Market for Other Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USDMillion)
Table 30.88 Antibody Discovery Services Market in North America, Historical Trends, 2017-2022 (USD Million)
Table 30.89 Antibody Discovery Services Market in North America, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USDMillion)
Table 30.90 Antibody Discovery Services Market in Europe, Historical Trends, 2017-2022 (USD Million)
Table 30.91 Antibody Discovery Services Market in Europe, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.92 Antibody Discovery Services Market in Asia, Historical Trends, 2017-2022 (USD Million)
Table 30.93 Antibody Discovery Services Market in Asia, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.94 Antibody Discovery Services Market in Latin America, Historical Trends, 2017-2022 (USD Million)
Table 30.95 Antibody Discovery Services Market in Latin America, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USDMillion)
Table 30.96 Antibody Discovery Services Market in Middle East and North Africa, Historical Trends, 2017-2022 (USD Million)
Table 30.97 Antibody Discovery Services Market in Middle East and North Africa, Forecasted Estimates, 2023-2035, Conservative, Base and OptimisticScenarios (USD Million)
Table 30.98 Antibody Discovery Services Market in Rest of the World, Historical Trends, 2017-2022 (USD Million)
Table 30.99 Antibody Discovery Services Market in Rest of the World, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USDMillion)
Table 30.100 Global Antibody Discovery Technologies Market, Historical Trends (2017-2022)
Table 30.101 Global Antibody Discovery Technologies Market, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.102 Antibody Discovery Technologies Market for Monoclonal Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.103 Antibody Discovery Technologies Market for Monoclonal Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and OptimisticScenarios (USD Million)
Table 30.104 Antibody Discovery Technologies Market for Bispecific Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.105 Antibody Discovery Technologies Market for Bispecific Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and OptimisticScenarios (USD Million)
Table 30.106 Antibody Discovery Technologies Market for Other Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.107 Antibody Discovery Technologies Market for Other Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.108 Antibody Discovery Technologies Market in North America, Historical Trends, 2017-2022 (USD Million)
Table 30.109 Antibody Discovery Technologies Market in North America, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.110 Antibody Discovery Technologies Market in Europe, Historical Trends, 2017-2022 (USD Million)
Table 30.111 Antibody Discovery Technologies Market in Europe, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.112 Antibody Discovery Technologies Market in Asia, Historical Trends, 2017-2022 (USD Million)
Table 30.113 Antibody Discovery Technologies Market in Asia, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.114 Humira®: Annual Sales, 2016-2022 (USD Billion)
Table 30.115 Keytruda®: Annual Sales, 2016-2022 (USD Billion)
Table 30.116 Stelara®: Annual Sales, 2016-2022 (USD Billion)
Table 30.117 Opdivo®: Annual Sales, 2016-2022 (USD Billion)
Table 30.118 Darzalex®: Annual Sales, 2016-2022 (CHF Million)
Source 1: https://www.pharmasalmanac.com/articles/what-do-you-consider-the-biggest-challenge-that-the-pharma/biopharma-industry-currently-faces
Source 2: https://www.sciencedirect.com/science/article/pii/S2049080114000624
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES